Korean J Asthma Allergy Clin Immunol.  2009 Jun;29(2):127-131.

Successful Desensitization to Epirubicin in a Breast Cancer Patient with Doxorubicin Hypersensitivity

Abstract

Doxorubicin, a chemotherapeutic agent of the anthracycline family, has commonly been used to treat a wide range of cancers including leukemia, Hodgkin's lymphoma, and cancers of the breast, uterus, ovary and bladder. Hypersensitivity is a rare adverse reaction to anthracyclines including daunorubicin, idarubicin and epirubicin. Although cross-reactivity among chemotherapeutic agents of the anthracycline family is not completely established, these agents are not clinically recommended if a patient has show hypersensitivity reaction to any anthracyclines. Desensitization is an alternative treatment option to overcome hypersensitivity reaction to anthracyclines, but cases of anthracycline desensitization have rarely been reported till now. We report successful epirubucin desensitization in a breast cancer patient with doxorubicin hypersensitivity.


MeSH Terms

Anthracyclines
Breast
Breast Neoplasms
Daunorubicin
Doxorubicin
Epirubicin
Female
Hodgkin Disease
Humans
Hypersensitivity
Idarubicin
Leukemia
Ovary
Urinary Bladder
Uterus
Anthracyclines
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Full Text Links
  • KJAACI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr